Sara Donati

1.1k total citations
40 papers, 756 citations indexed

About

Sara Donati is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Sara Donati has authored 40 papers receiving a total of 756 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 11 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Sara Donati's work include Cancer Treatment and Pharmacology (22 papers), Chemotherapy-induced cardiotoxicity and mitigation (11 papers) and Breast Cancer Treatment Studies (6 papers). Sara Donati is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), Chemotherapy-induced cardiotoxicity and mitigation (11 papers) and Breast Cancer Treatment Studies (6 papers). Sara Donati collaborates with scholars based in Italy, Nigeria and Brazil. Sara Donati's co-authors include Pierfranco Conté, Alessandra Gennari, B. Salvadori, Mario Del Tacca, Romano Danesi, Cinzia Orlandini, D. Amoroso, Andrea Camerini, Valentina Guarneri and Carmelo Bengala and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Sara Donati

37 papers receiving 724 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sara Donati Italy	16	497	220	191	105	103	40	756
Cristina Ghiotto Italy	16	362 0.7×	234 1.1×	179 0.9×	101 1.0×	156 1.5×	48	937
Rümeysa Çiftçi Türkiye	16	385 0.8×	140 0.6×	249 1.3×	134 1.3×	70 0.7×	43	776
Tiziano Camacci Italy	14	276 0.6×	146 0.7×	241 1.3×	264 2.5×	84 0.8×	18	814
Jean Philippe Spano France	11	418 0.8×	220 1.0×	363 1.9×	156 1.5×	43 0.4×	16	815
Irene De Santo Italy	9	394 0.8×	213 1.0×	342 1.8×	169 1.6×	44 0.4×	13	692
Corrine Zarwan United States	13	691 1.4×	214 1.0×	200 1.0×	321 3.1×	47 0.5×	27	1.1k
Roberto Díaz United States	19	353 0.7×	113 0.5×	321 1.7×	217 2.1×	110 1.1×	57	1.0k
Daniel Buergy Germany	13	289 0.6×	143 0.7×	152 0.8×	157 1.5×	93 0.9×	29	674
Keith Unger United States	17	398 0.8×	169 0.8×	373 2.0×	107 1.0×	154 1.5×	64	940
Loredana Miglietta Italy	17	296 0.6×	137 0.6×	116 0.6×	145 1.4×	29 0.3×	48	605

Countries citing papers authored by Sara Donati

Since Specialization

Citations

This map shows the geographic impact of Sara Donati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Donati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Donati more than expected).

Fields of papers citing papers by Sara Donati

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Donati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Donati. The network helps show where Sara Donati may publish in the future.

Co-authorship network of co-authors of Sara Donati

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Donati. A scholar is included among the top collaborators of Sara Donati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Donati. Sara Donati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Canale, Maria Laura, Giancarlo Casolo, Sara Donati, et al.. (2023). Baseline Troponin Level and Cardiac Toxicity in HER2-positive Early Breast Cancer Patients Receiving Trastuzumab. In Vivo. 37(5). 2139–2146.

Canale, Maria Laura, Andrea Camerini, Jacopo Del Meglio, et al.. (2017). Applicazione di un percorso diagnostico-terapeutico assistenziale di cardioncologia per la rilevazione e la gestione del danno cardiaco da trattamenti oncologici in ambito ospedaliero. Giornale italiano di cardiologia. 18(11). 760–763.

Mencoboni, Manlio, Rosangela Filiberti, Alessandro Del Conte, et al.. (2017). Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC. Anticancer Research. 37(6). 3189–3194. 23 indexed citations

Camerini, Andrea, C. Puccetti, Sara Donati, et al.. (2015). Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). BMC Cancer. 15(1). 359–359. 61 indexed citations

Camerini, Andrea, Sara Donati, Paolo Viacava, et al.. (2011). Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer. Journal of Experimental & Clinical Cancer Research. 30(1). 38–38. 13 indexed citations

Camerini, Andrea, Ornella Garrone, C. Valsuani, et al.. (2009). Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone receptor-positive metastatic breast cancer patients. Cancer Biology & Therapy. 8(15). 1450–1455. 2 indexed citations

Camerini, Andrea, C. Valsuani, Francesca Mazzoni, et al.. (2009). Phase II trial of single-agent oral vinorelbine in elderly (≥70 years) patients with advanced non-small-cell lung cancer and poor performance status. Annals of Oncology. 21(6). 1290–1295. 18 indexed citations

Lopatriello, Stefania, D. Amoroso, Sara Donati, et al.. (2008). The CAP-CR study: Direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine. European Journal of Cancer. 44(17). 2615–2622. 15 indexed citations

Sgambato, Alessandro, Andrea Camerini, D. Amoroso, et al.. (2007). Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma. Cancer Biology & Therapy. 6(12). 1840–1846. 29 indexed citations

10.

Camerini, Andrea, et al.. (2007). Ipsilateral right testicular metastasis from renal cell carcinoma in a responder patient to interleukine‐2 treatment. International Journal of Urology. 14(3). 259–260. 18 indexed citations

11.

Filippi, Sandra, Andrea Morelli, Linda Vignozzi, et al.. (2006). Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. 11. 10 indexed citations

12.

Conté, Pierfranco, Sara Donati, Alessandra Gennari, et al.. (2005). Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study. British Journal of Cancer. 93(4). 406–411. 14 indexed citations

13.

Guarneri, Valentina, Carmelo Bengala, Cinzia Orlandini, et al.. (2004). HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support. Bone Marrow Transplantation. 34(5). 413–417. 12 indexed citations

14.

Fogli, Stefano, Romano Danesi, Alessandra Gennari, et al.. (2002). Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. Annals of Oncology. 13(6). 919–927. 47 indexed citations

15.

Conté, Pierfranco, Alessandra Gennari, Valentina Guarneri, et al.. (2001). Epirubicin/taxane combinations in breast cancer: experience from several Italian trials.. PubMed. 15(5 Suppl 7). 21–3. 3 indexed citations

16.

Conté, Pierfranco, Alessandra Gennari, Elisabetta Landucci, et al.. (2001). New combinations with epirubicin in advanced breast cancer.. IRIS UNIMORE (University of Modena and Reggio Emilia). 15(5 Suppl 7). 24–7. 3 indexed citations

17.

Conté, Pierfranco, Alessandra Gennari, Sara Donati, et al.. (2001). Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*. Breast Cancer Research and Treatment. 68(2). 171–179. 55 indexed citations

18.

Venturini, M., Andrea Michelotti, Paola Papaldo, et al.. (2001). Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. Annals of Oncology. 12(8). 1097–1106. 21 indexed citations

19.

Conté, Pierfranco, B. Salvadori, Sara Donati, Elisabetta Landucci, & Alessandra Gennari. (2001). Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer. Seminars in Oncology. 28(2D). 15–17. 2 indexed citations

20.

Salardi, Silvana, E Cacciari, Sara Donati, et al.. (1995). An 8‐year follow‐up of anti‐insulin antibodies in diabetic children: relation to insulin autoantibodies, HLA type, β‐cell function, clinical course and type of insulin therapy. Acta Paediatrica. 84(6). 639–645. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact